Pfizer appoints chief scientific officer for neuroscience research

Pfizer Pfizer Inc. has announced that Dr. Ole Isacson, a world-renowned scientist and thought leader in neurology, will become Chief Scientific Officer of the Neuroscience Research Unit and Senior Vice President, effective September 16. Dr. Isacson is a Professor of Neurology at Harvard Medical School, and will continue to serve in an educational role. He is also a founding director of the Neuroregeneration Institute at McLean Hospital. Dr. Isacson will report directly to Mikael Dolsten, President of Worldwide Research and Development.

Dr. Isacson received his Medical Bachelor and Doctor of Medicine degrees from the University of Lund in Sweden and held a two year postdoctoral fellowship at Cambridge University in England before joining Harvard in 1989. Over the course of two decades, his lab has become known as one of the most recognized academic research centers for Parkinson's disease and other neurodegenerative disorders.

"Dr. Isacson's deep expertise in neurodegenerative disorders is well-aligned with our work in Alzheimer's and Parkinson's disease, where we are working to advance potential breakthrough therapies to fill the tremendous unmet need that exists for patients," said Dr. Dolsten. "In addition, his strong ties in the local academic community will be important as our Cambridge site continues to drive collaborations with leading scientific and academic institutions that can help us speed the pace of discovery."

Additional Internal Promotions
The appointment of Dr. Isacson cements the scientific leadership team at Pfizer’s Worldwide Research and Development hub in Cambridge, Mass. In May of this year Pfizer promoted two leading scientists to Chief Scientific Officer positions. Greg LaRosa, Ph.D., was named Senior Vice President and Chief Scientific Officer of the Rare Disease Research Unit. Prior to this role, Dr. LaRosa was head of Biology for the Rare Disease Unit and held responsibility for setting portfolio strategies, overseeing pre-clinical project progression and working with the leadership team to set forth strategy for the unit across Pfizer. Dr. LaRosa received a Ph.D. from Harvard University in Molecular, Cellular and Developmental Biology and has more than 23 years of experience in rare disease and inflammation drug discovery and development.

Michael Vincent, M.D., Ph.D., was named Senior Vice President and Chief Scientific Officer of the Inflammation and Immunology Research Unit. Since joining Pfizer in 2011, Dr. Vincent has held numerous scientific leadership roles, most recently as Clinical Head for Pharmatherapeutics and Biotherapeutics. Before joining Pfizer, Dr. Vincent held several positions within Medical Sciences at Amgen. Dr. Vincent earned his Ph.D. and M.D. degrees from Indiana University. He completed his residency and began his post-doctoral training at the University of Vermont and ultimately completed this at Harvard University, where he also served as a staff physician.

About Pfizer Cambridge Worldwide Research and Development
Pfizer's Cambridge campus is home to four of the company's six core therapeutic areas: Cardiovascular and Metabolic Disease; Inflammation and Immunology; Neuroscience; and Rare Disease. The site drives discovery science and early clinical development on behalf of Pfizer Worldwide Research and Development, with a focus on advancing disruptive science and accelerating potential breakthrough therapies, while fostering collaboration across the Massachusetts biomedical ecosystem to deliver innovation to patients.

Pfizer employs more than 2,000 colleagues throughout Massachusetts. In addition to its Worldwide Research and Development hub in Cambridge, Massachusetts is home to Pfizer's research and manufacturing facility in Andover and is the global headquarters for its Centers for Therapeutic Innovation (CTI) in Boston. Last year, Pfizer announced an expansion of its Cambridge presence with the consolidation of Pfizer's three other leased Boston and Cambridge centers into one campus. CTI will move to Cambridge in 2017, as Pfizer prepares to open a second building adjacent to its current campus.

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...